Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0021 | 1 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0021 | 1 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0021 | 1 | 0.5 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0021 | 1 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0021 | 1 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 1 | 1 |
Toxoplasma gondii | exonuclease III APE | 0.0021 | 1 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0021 | 1 | 0.5 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 1 | 0.5 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0021 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0021 | 1 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0014 | 0.3523 | 0.3523 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0021 | 1 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0021 | 1 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0021 | 1 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0021 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0021 | 1 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 1 | 0.5 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0021 | 1 | 1 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 1 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0021 | 1 | 0.5 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0014 | 0.3523 | 0.3523 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0014 | 0.3523 | 0.3523 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.